Video: New Results From One of the World's Largest Breast Cancer Trials Herald Hope for Thousand...( Benefits of Arimidex (anastrozole) o...),Health

Benefits of Arimidex (anastrozole) over tamoxifen at preventing all forms of breast cancer recurrence increase over time - even four years after

treatment ends

SAN ANTONIO, Dec. 14 /PRNewswire/ -- New data from ATAC*, one of the world's largest and longest-running studies in postmenopausal women with early breast cancer, reinforce that anastrozole can help many more women live cancer-free, for longer. For the first time, anastrozole has been shown to be the only treatment of its type to be increasingly better than tamoxifen in preventing tumours from returning.(1),(2) If cancer returns, women are much more likely to die - therefore, preventing breast cancer from returning ("recurrence") is key to saving lives.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/astrazeneca/30949/

The landmark results - presented today at the prestigious annual San Antonio Breast Cancer Symposium (SABCS), USA and also published online in The Lancet Oncology - show that even four years after a woman's treatment ends, the protective effect of anastrozole in reducing the risk of hormone-sensitive early breast cancer from returning continues to increase. Overall, women in the ATAC trial taking anastrozole were 24% less likely to have their cancer come back, compared with those taking tamoxifen.(1),(2) This demonstrates the long-term impact of treatment decisions made at diagnosis and confirms the importance of starting treatment with anastrozole to help more women beat this devastating disease. Breast cancer currently affects 1.1 million women worldwide per year 3 and hormone-sensitive early disease accounts for around 75% of all cases of breast cancer in postmenopausal women.(4)

Presenting the data at SABCS, Professor John Forbes, Newcastle Mater Misericordiae Hospital, Australia commented: "Preventing recurrence i
'/>"/>